Institute for Wealth Management LLC. purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,672 shares of the life sciences company’s stock, valued at approximately $288,000.

Other hedge funds also recently added to or reduced their stakes in the company. Penserra Capital Management LLC increased its stake in shares of Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after buying an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC raised its holdings in Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares in the last quarter. Patten Group Inc. raised its holdings in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after acquiring an additional 25 shares in the last quarter. NN Investment Partners Holdings N.V. raised its holdings in Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after acquiring an additional 100 shares in the last quarter. Finally, Probity Advisors Inc. acquired a new stake in Illumina in the first quarter valued at $204,000. 93.32% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the sale, the senior vice president now owns 24,908 shares in the company, valued at $5,263,807.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Omead Ostadan sold 1,672 shares of the stock in a transaction on Friday, July 7th. The stock was sold at an average price of $172.73, for a total value of $288,804.56. Following the sale, the executive vice president now owns 26,242 shares in the company, valued at approximately $4,532,780.66. The disclosure for this sale can be found here. Insiders sold 195,043 shares of company stock valued at $37,848,873 in the last quarter. 1.60% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/03/institute-for-wealth-management-llc-buys-shares-of-1672-illumina-inc-ilmn.html.

ILMN has been the topic of a number of research analyst reports. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price objective on the stock in a research note on Monday, June 12th. BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Morgan Stanley reissued an “underweight” rating and issued a $122.00 target price (up previously from $115.00) on shares of Illumina in a research report on Monday, July 10th. Barclays PLC restated a “hold” rating and issued a $150.00 target price on shares of Illumina in a research note on Wednesday, July 19th. Finally, Canaccord Genuity restated a “hold” rating and issued a $170.00 target price on shares of Illumina in a research note on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. Illumina has an average rating of “Hold” and an average target price of $183.00.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded up 0.45% during trading on Tuesday, reaching $203.15. The company had a trading volume of 71,192 shares. The company has a market cap of $29.66 billion, a P/E ratio of 40.76 and a beta of 0.76. The firm has a 50-day moving average of $201.31 and a 200-day moving average of $183.47. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.34.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662.00 million for the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 earnings per share. On average, equities research analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current year.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.